{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:59:00Z","timestamp":1791464340516,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.coph.2018.05.006","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:32:33Z","timestamp":1527813153000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["The antimalarial pipeline"],"prefix":"10.1016","volume":"42","author":[{"given":"Rob","family":"Hooft van Huijsduijnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy NC","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.05.006_bib0005","unstructured":"World Health Organization. Overview of malaria treatment. http:\/\/wwwwhoint\/malaria\/areas\/treatment\/overview\/en\/. 2018 (accessed March 2018)."},{"key":"10.1016\/j.coph.2018.05.006_bib0010","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1128\/AAC.00358-10","article-title":"Amodiaquine resistance in Plasmodium falciparum malaria in Afghanistan is associated with the pfcrt SVMNT allele at codons 72 to 76","volume":"54","author":"Beshir","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2018.05.006_bib0015","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","article-title":"Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number","volume":"364","author":"Price","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.05.006_bib0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","article-title":"A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study","volume":"17","author":"Witkowski","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2018.05.006_bib0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","article-title":"Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study","volume":"17","author":"Amato","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2018.05.006_bib0030","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc0805011","article-title":"Evidence of artemisinin-resistant malaria in western Cambodia","volume":"359","author":"Noedl","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.05.006_bib0035","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nm0316-220","article-title":"Back on TRAC: new trial launched in bid to outpace multidrug-resistant malaria","volume":"22","author":"Maxmen","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2018.05.006_bib0040","doi-asserted-by":"crossref","first-page":"e000371","DOI":"10.1136\/bmjgh-2017-000371","article-title":"Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence","volume":"2","author":"Schallig","year":"2017","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.coph.2018.05.006_bib0045","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","article-title":"Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial","volume":"376","author":"Dondorp","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.05.006_bib0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(05)67176-0","article-title":"Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial","volume":"366","author":"Dondorp","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.05.006_bib0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1475-2875-13-50","article-title":"Introducing the concept of a new pre-referral treatment for severely ill febrile children at community level: a sociological approach in Guinea-Bissau","volume":"13","author":"Vermeersch","year":"2014","journal-title":"Malar J"},{"key":"10.1016\/j.coph.2018.05.006_bib0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4269\/ajtmh.16-0332","article-title":"Azithromycin for malaria?","volume":"95","author":"Rosenthal","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coph.2018.05.006_bib0065","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","article-title":"Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial","volume":"4","author":"Markowitz","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.coph.2018.05.006_sbref0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"Burrows","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.coph.2018.05.006_sbref0075","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.50","article-title":"Malaria","volume":"3","author":"Phillips","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"10.1016\/j.coph.2018.05.006_sbref0080","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12936-017-1731-1","article-title":"Malaria parasite clearance","volume":"16","author":"White","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.coph.2018.05.006_bib0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1126\/science.aan4472","article-title":"Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics","volume":"359","author":"Cowell","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.coph.2018.05.006_bib0090","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1124\/dmd.115.069187","article-title":"KAE609 (Cipargamin), a new spiroindolone agent for the treatment of malaria: evaluation of the absorption, distribution, metabolism, and excretion of a single oral 300-mg dose of [14C]KAE609 in healthy male subjects","volume":"44","author":"Huskey","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.coph.2018.05.006_bib0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12936-017-2162-8","article-title":"A phase 1 evaluation of the pharmacokinetic\/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine","volume":"17","author":"Leong","year":"2018","journal-title":"Malar J"},{"key":"10.1016\/j.coph.2018.05.006_bib0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9735","article-title":"Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase","volume":"9","author":"Paquet","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2018.05.006_bib0105","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.7b00299","article-title":"Seeking the elusive long-acting ozonide: discovery of artefenomel (OZ439)","author":"Kim","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2018.05.006_bib0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12916-017-0940-3","article-title":"A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria","volume":"15","author":"Macintyre","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.coph.2018.05.006_bib0115","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00172-17","article-title":"Plasmodium falciparum K13 mutations differentially impact ozonide susceptibility and parasite fitness in vitro","volume":"8","author":"Straimer","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.coph.2018.05.006_bib0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1473-3099(15)00320-5","article-title":"Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial","volume":"16","author":"Phyo","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2018.05.006_bib0125","article-title":"A randomized trial of the prophylactic activity of DSM265 against pre-erythrocytic Plasmodium falciparum controlled human malaria infection by mosquito bites and direct venous inoculation","author":"Murphy","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2018.05.006_bib0130","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1473-3099(17)30139-1","article-title":"DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection","volume":"17","author":"Sulyok","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2018.05.006_bib0135","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1080\/07391102.2014.979231","article-title":"Origins of the specificity of inhibitor P218 toward wild-type and mutant PfDHFR: a molecular dynamics analysis","volume":"33","author":"Abbat","year":"2015","journal-title":"J Biomolec Struct Dyn"},{"key":"10.1016\/j.coph.2018.05.006_bib0140","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-12-187","article-title":"Designing the next generation of medicines for malaria control and eradication","volume":"12","author":"Burrows","year":"2013","journal-title":"Malar J"},{"key":"10.1016\/j.coph.2018.05.006_bib0145","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2147\/DDDT.S61443","article-title":"Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date","volume":"10","author":"Ebstie","year":"2016","journal-title":"Drug Des Dev Therapy"},{"key":"10.1016\/j.coph.2018.05.006_sbref0150","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12936-018-2198-4","article-title":"A novel immortalized hepatocyte-like cell line (imHC) supports in vitro liver stage development of the human malarial parasite Plasmodium vivax","volume":"17","author":"Pewkliang","year":"2018","journal-title":"Malar J"},{"key":"10.1016\/j.coph.2018.05.006_bib0155","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","article-title":"Ivermectin\u2014old drug, new tricks?","volume":"33","author":"Laing","year":"2017","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.coph.2018.05.006_bib0160","unstructured":"Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong'o BO, Chen T, et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis."},{"key":"10.1016\/j.coph.2018.05.006_bib0165","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/cid\/ciu797","article-title":"Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial","volume":"60","author":"Ouedraogo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2018.05.006_bib0170","doi-asserted-by":"crossref","first-page":"e1005763","DOI":"10.1371\/journal.ppat.1005763","article-title":"Open source drug discovery with the Malaria Box compound collection for neglected diseases and beyond","volume":"12","author":"Van Voorhis","year":"2016","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.coph.2018.05.006_bib0175","article-title":"Controlled human malaria infection: applications, advances and challenges","author":"Stanisic","year":"2017","journal-title":"Infect Immun"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:49:57Z","timestamp":1761461397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218300213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":35,"alternative-id":["S1471489218300213"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.05.006","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The antimalarial pipeline","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}